The addition of anlotinib reduces the incidence of radiation and immunotherapy-induced pneumonia

© The Author(s) 2023. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http:// creat iveco mmons. org/ licen ses/ by/4. 0/. The Creative Commons Public Domain Dedication waiver (http:// creat iveco mmons. org/ publi cdoma in/ zero/1. 0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. Journal of Translational Medicine

The addition of anlotinib reduces the incidence of radiation and immunotherapy-induced pneumonia Linlin Yang 2,3 † , Qian Zhao 1,2,3 † , Jinming Yu 1,2,3* and Linlin Wang 2,3*   To the editor, The synergistic effect of immunotherapy and radiotherapy has been widely recognized.However, the cumulative lung toxicity of thoracic radiotherapy (TRT) combined with PD-1/PD-L1 inhibitors cannot be overlooked in clinical practice.In the PACIFIC study, the incidence of pneumonitis was significantly higher in the immunotherapy consolidation group compared to the placebo group (33.9% vs. 24.8%)[1].However, in the IMpower150 study, the addition of bevacizumab (ABCP group) resulted in a lower incidence of pneumonitis compared to the ACP group, and the resolution of inflammation was better (4.3% vs. 2.8%, 29.4% vs. 9.1%) [2].Preclinical studies have also shown that anti-vascular endothelial growth factor antibodies could prevent pulmonary alveolar leakage caused by increased vascular permeability, thereby alleviating immunotherapy-induced pneumonitis [3].Therefore, we hypothesize that anti-angiogenic drugs may reduce the incidence of pneumonitis caused by the combination of radiotherapy and immunotherapy.
The study was approved by the Ethics Committee of Shandong Cancer Hospital.As it was a retrospective analysis, informed consent was not required.We included patients with non-small cell lung cancer (NSCLC) who received TRT and at least 2 cycles of immunotherapy, with the interval between the two treatments not exceeding 6 months.The primary endpoint was treatment-related pulmonary toxicity, assessed using the Common Terminology Criteria for Adverse Events (version 5.0).
With the combined immunotherapy and TRT has become the standard treatment for NSCLC, the overlapping pulmonary toxicity of these two treatments has emerged as a common and severe complication.
Previous preclinical studies have shown that bevacizumab can alleviate immunotherapy-induced pneumonitis.Additionally, the IMpower150 study also found that the addition of bevacizumab resulted in a lower incidence of pneumonitis.However, in this current study, the application of bevacizumab did not show a lower incidence of pneumonitis.Instead, a multi-targeted small molecule anti-angiogenic drug, anlotinib, provided a surprising result, reducing the occurrence of pneumonitis caused by the combination of TRT and immunotherapy (p = 0.038, HR = 0.400, 95% CI 0.168-0.950).Nevertheless, the mechanisms behind this effect still require further investigation.
Currently, corticosteroids are commonly used in clinical practice to treat radiation-immunotherapy-related pneumonitis, but they may affect the anti-tumor efficacy of drugs [4].On the other hand, anlotinib has been reported to exhibit synergistic effects with immunotherapy and to reverse radiotherapy resistance in NSCLC [5].Our research results indicate that anlotinib may be a favorable treatment option for patients receiving combined radiotherapy and immunotherapy.
This study offers a new alternative for clinical treatment approaches; however, it necessitates larger prospective studies to explore safety and efficacy aspects further.

Table 1
Clinical characteristics of patients Cumulative incidence of grade ≥ 2 pneumonitis